Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice
Abstract Antibodies have been explored extensively as a potential therapeutic for Alzheimer’s disease, where amyloid-β (Aβ) peptides and the tau protein deposit in patient brains. While the major focus of antibody-based therapy development was on Aβ, arguably with limited success in clinical trials,...
Guardado en:
Autores principales: | Julia van der Hoven, Annika van Hummel, Magdalena Przybyla, Prita R. Asih, Mehul Gajwani, Astrid F. Feiten, Yazi D. Ke, Arne Ittner, Janet van Eersel, Lars M. Ittner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7542fd4f0b3143c8a94362ae7f8f1328 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tau exacerbates excitotoxic brain damage in an animal model of stroke
por: Mian Bi, et al.
Publicado: (2017) -
Development of P301S tau seeded organotypic hippocampal slice cultures to study potential therapeutics
por: James M. McCarthy, et al.
Publicado: (2021) -
Differential Effects of Human P301L Tau Expression in Young versus Aged Mice
por: Holly C. Hunsberger, et al.
Publicado: (2021) -
Expression of P301L-hTau in mouse MEC induces hippocampus-dependent memory deficit
por: Xinghua Liu, et al.
Publicado: (2017) -
Acta Nº301
por: Banco Central de Chile
Publicado: (2019)